Mounting a fightback: Covid-19 vaccine developers reach last leg of trials

As US regulators tighten the scrutiny around approvals, companies have announced their intention to put their trial data in public domain for scientific enquiry to remove any doubt about safety and efficacy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2FSnOFe
via IFTTT